BioInvent International AB (publ)

OTCPK:BOVN.F Stock Report

Market Cap: US$249.2m

BioInvent International Management

Management criteria checks 4/4

BioInvent International's CEO is Martin Welschof, appointed in Jan 2018, has a tenure of 4.75 years. total yearly compensation is SEK4.75M, comprised of 56.9% salary and 43.1% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $85.91K. The average tenure of the management team and the board of directors is 4.8 years and 5.3 years respectively.

Key information

Martin Welschof

Chief executive officer

SEK 4.7m

Total compensation

CEO salary percentage56.9%
CEO tenure4.8yrs
CEO ownership0.03%
Management average tenure4.8yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martin Welschof's remuneration changed compared to BioInvent International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-SEK 42m

Mar 31 2022n/an/a

-SEK 266m

Dec 31 2021SEK 5mSEK 3m

-SEK 278m

Sep 30 2021n/an/a

-SEK 171m

Jun 30 2021n/an/a

-SEK 141m

Mar 31 2021n/an/a

-SEK 123m

Dec 31 2020SEK 5mSEK 3m

-SEK 76m

Sep 30 2020n/an/a

-SEK 146m

Jun 30 2020n/an/a

-SEK 150m

Mar 31 2020n/an/a

-SEK 144m

Dec 31 2019SEK 4mSEK 2m

-SEK 139m

Sep 30 2019n/an/a

-SEK 130m

Jun 30 2019n/an/a

-SEK 116m

Mar 31 2019n/an/a

-SEK 126m

Dec 31 2018SEK 3mSEK 800k

-SEK 123m

Compensation vs Market: Martin's total compensation ($USD437.09K) is below average for companies of similar size in the US market ($USD1.55M).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.

CEO

Martin Welschof (61 yo)

4.8yrs

Tenure

SEK 4,747,000

Compensation

Dr. Martin Welschof, Ph D has been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018.He i...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Welschof
President & CEO4.8yrsSEK 4.75m0.034%
$ 85.9k
Stefan Ericsson
Chief Financial Officer6.8yrsno data0.012%
$ 30.7k
Marie Moores
Chief Operating Officerless than a yearno datano data
Kristoffer Hansson
Senior Vice President of Technical Operations6.1yrsno data0.034%
$ 85.5k
Björn Frendéus
Chief Scientific Officerno dataSEK 2.35m0.036%
$ 88.5k
Cecilia Hofvander
Senior Director of Investor Relations1.7yrsno datano data
Andres McAllister
Chief Medical Officer5.8yrsno data0.0046%
$ 11.5k
Ingrid Teige
Head of Preclinical Researchno datano datano data
Sylvie Ryckebusch
Chief Business Officerless than a yearno datano data

4.8yrs

Average Tenure

57yo

Average Age

Experienced Management: BOVN.F's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernd Seizinger
Independent Director4.8yrsSEK 420.00k0.046%
$ 115.1k
Leonard Kruimer
Independent Chairman of the Board4.8yrsSEK 682.00k0.025%
$ 62.5k
Thomas Hecht
Independent Director2.3yrsSEK 360.00kno data
Vincent Ossipow
Independent Director1.5yrsSEK 375.00kno data
Alexander Rudensky
Member of Scientific Advisory Board5.8yrsno datano data
Falk Nimmerjahn
Member of Scientific Advisory Board5.8yrsno datano data
Dharminder Chahal
Independent Director5.8yrsSEK 375.00k0.45%
$ 1.1m
Vessela Alexieva
Employee Representative Director9yrsno data0.0014%
$ 3.6k
Kristoffer Bissessar
Independent Director2.4yrsSEK 395.00k0.023%
$ 57.5k
Rienk Offringa
Member of Scientific Advisory Board5.8yrsno datano data
Mark Cragg
Member of Scientific Advisory Boardno datano datano data
Stephen Beers
Member of Scientific Advisory Boardno datano datano data

5.3yrs

Average Tenure

63yo

Average Age

Experienced Board: BOVN.F's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/10/26 21:01
End of Day Share Price 2022/07/29 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Camilla OxhamreCarnegie Investment Bank AB
Mattias HäggblomDanske Bank